A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
for
Solid Tumor
Location: Boston MA, New Haven CT, The Bronx NY, Montreal,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06619587
Phase1, Recruiting
Featured
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
for
Neoplasms
Location: New Haven CT, Toronto, Sarasota FL, Houston TX,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06884618
Phase1, Recruiting
Active & Responsive
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
for
Solid Tumor
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: Biohaven Therapeutics Ltd.
Sex: All
Age: 18+
Code: NCT06384807
Phase1, Phase2, Recruiting
Active & Responsive
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Alterome Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06835569
Phase1, Recruiting
Interested in new solid tumor trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT06682793
Phase1, Phase2, Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase1, Recruiting
Active & ResponsiveNew
REC-7735 in Participants With Solid Tumors
for
Solid Tumors
Location: Grand Rapids MI
Sponsor: Recursion Pharmaceuticals Inc.
Sex: All
Age: 18+
Code: NCT07819136
Phase1, Phase2, Recruiting
Active & ResponsiveNew
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
for
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Location: Fairfax VA, Sarasota FL, Houston TX, San Antonio TX
Sponsor: Myricx Pharma Limited
Sex: All
Age: 18+
Code: NCT07807241
Phase1, Recruiting
Active & Responsive
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
for
Advanced Solid Tumor
Location: East Providence RI, Charleston SC, Huntersville NC,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06750185
Phase1, Phase2, Recruiting
Active & Responsive
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: Fairfax VA, Charleston SC, Detroit MI, Houston TX,
Sponsor: A2A Pharmaceuticals Inc.
Sex: All
Age: 18+
Code: NCT06136884
Phase1, Recruiting
Active & Responsive
FOG-001 in Locally Advanced or Metastatic Solid Tumors
for
Cancer, Colorectal Cancer, Solid Tumor,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: Parabilis Medicines, Inc.
Sex: All
Age: 18+
Code: NCT05919264
Phase1, Phase2, Recruiting
Active & Responsive
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
for
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer,
Location: New Haven CT, Lake Success NY, New York NY, Fairfax VA,
Sponsor: Cogent Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT07361562
Phase1, Recruiting
Active & Responsive
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
for
Solid Tumor, Adult, Colorectal Cancer,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT04981119
Recruiting
Active & Responsive
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
for
Solid Tumor
Location: Canton OH, Cleveland OH
Sponsor: Lamassu Bio Inc
Sex: All
Age: 18+
Code: NCT06578624
Phase1, Phase2, Recruiting
Active & Responsive
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
for
Advanced Solid Tumor
Location: Fairfax VA, Grand Rapids MI, Nashville TN, Dallas TX,
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06066424
Phase1, Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT06051695
Phase1, Phase2, Recruiting
Active & Responsive
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors